ETF Holdings Breakdown of URGN

News associated with URGN

MetLife Investment Management LLC Buys 2,727 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

MetLife Investment Management LLC increased its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 13.6% during the fourth quarter, HoldingsChannel reports. The firm owned 22,766 shares of the company’s stock after acquiring an additional 2,727 shares during the period. MetLife Investment Management LLC’s holdings in UroGen Pharma were worth $242,000 as of its […] - 2025-05-08 08:02:47

UroGen Pharma Ltd. (NASDAQ:URGN) Receives $32.86 Average PT from Analysts

Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. […] - 2025-05-08 05:52:55

Alliancebernstein L.P. Acquires 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Alliancebernstein L.P. grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 751.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 199,259 shares of the company’s stock after acquiring an additional 175,859 shares during the quarter. Alliancebernstein L.P.’s holdings in UroGen Pharma were worth $2,122,000 at the end […] - 2025-04-17 07:30:58

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright

UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from $64.00 to $55.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 408.32% from the stock’s previous close. […] - 2025-03-13 06:41:05

UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report issued on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock. Other research analysts have also issued reports about the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in […] - 2025-03-11 05:50:47

Oppenheimer & Co. Inc. Purchases Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN)

Oppenheimer & Co. Inc. acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,875 shares of the company’s stock, valued at approximately $126,000. Several other […] - 2025-03-10 08:16:51

UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $64.00 price objective on the stock. URGN has been the topic of several other reports. D. Boral Capital reiterated a […] - 2025-02-27 08:44:57

UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock. UroGen Pharma Trading Down 1.9 % NASDAQ:URGN opened at $10.56 on Tuesday. The company has a debt-to-equity ratio of […] - 2025-02-19 06:56:52

URGN institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	37,230	USD 397,244 5.2%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	20,517	USD 218,916
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	20,517	USD 218,916 5.2%
Total =		78,264	USD 835,076

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer